Джерело: European Cystic Fibrosis Society Standards of Care: Best Practice guidelines Journal of Cystic Fibrosis Alan R. Smith et. al., 2014

[1] DiSant'Agnese PA. Cystic fibrosis of the pancreas. Am J Med 1956;21:406–22.

[2] Shwachman H, Kulczycki LL. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child 1958;96:6–15.

[3] Doershuk CF, Matthews LW, Tucker AS, Nudleman H, Eddy G, Wise M, et al. A 5 year clinical evaluation of a therapeutic program for patients with cystic fibrosis. J Pediatr 1964;65:677–93.

[4] Warwick WJ, Pogue RE. The prognosis for children with cystic fibrosis based on reasoned approaches to therapy: past, present, and future. J Asthma Res 1968;5:277–84.

[5] Shwachman H, Kowalski M, Khaw KT. Cystic fibrosis: a new outlook. 70 patients above 25 years of age. Medicine 1977;56:129–49.

[6] Crozier DN. Cystic fibrosis: a not-so-fatal disease. Pediatr Clin North Am 1974;21:935–50.

[7] Gurwitz D, Corey M, Francis PW, Crozier D, Levison H. Perspectives in cystic fibrosis. Pediatr Clin North Am 1979;26:603–15.

[8] Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988;41:583–91.

[9] Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2011 annual data report; 2012 [Bethesda, Maryland].

[10] Cystic Fibrosis Canada. Canadian Cystic Fibrosis Patient Data Registry report. 2010; 2011 [Toronto].

[11] Cystic Fibrosis Foundation.

http://www.cff.org/LivingWithCF/CareCenterNetwork/QualityImprovement/; 2013.

[12] Salvatore D, Buzzetti R, Baldo E, Furnari ML, Lucidi V, Manunza D, et al. An overview of international literature from cystic fibrosis registries. Part 4: update 2011. J Cyst Fibros 2012;11:480–93.

[13] European cystic fibrosis society patient registry newsletter.

http://www.ecfs.eu/projects/ecfspr/newsletters; January 2013. [Issue 3].

[14] The ECFS Patient Registry annual data report. 2008–2009 data. version 03. Available from:

https://www.ecfs.eu/files/webfm/webfiles/File/ecfs_ registry/ECFSPR_Report0809_v32012.pdf; 2012.

[15] Kerem E, Viviani L, Zolin A, Macneill S, Hatziagorou E, Ellemunter H, et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the data of the ECFS Patient Registry. Eur Respir J 2013. http:// dx.doi.org/10.1183/09031936.00166412 [Epub ahead of print].

[16] Wiedemann B, Steinkamp G, Sens B, Stern M. The German Cystic Fibrosis Quality Assurance Project: clinical features in children and adults. Eur Respir J Eur Respir J 2001;17:1187–94. M. Stern et al. / Journal of Cystic Fibrosis 13 (2014) S43–S59 S59

[17] Gutierrez HH, Sanchez I, Schidlow DV. Cystic fibrosis care in Chile. Curr Opin Pulm Med 2009;15:632–7.

[18] Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, et al. Epidemiologic study of cystic fibrosis: design and implemen- tation of a prospective, multicentre, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pumonol 1999;28:231–41.

[19] Schechter MS. Benchmarking to improve the quality of cystic fibrosis care. Curr Opin Pulm Med 2012;18:596–601.

[20] Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, et al. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol 2010;45:934–44.

[21] Byrnes CA, Vidmar S, Cheney JL, Carlin JB, Armstrong DS, Cooper PJ, et al. Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. Thorax 2013;68:643–51.

[22] Martin B, Schechter MS, Jaffe A, Cooper P, Bell SC, Ranganathan S. Comparison of the US and Australian cystic fibrosis registries: the impact of newborn screening. Pediatrics 2012;129:48–55.

[23] Closing the quality gap: revisiting the state of the science series: quality improvement interventions to address health disparities. Review protocol. Rockville, MD: Agency for Healthcare Research

and Quality; 2011 [http://www.ahrq.gov/clinic/tp/gapdisptp.htm].

[24] Berwick DM. The science of improvement. JAMA 2008;299:1182–4.

[25] Shojania KG, Grimshaw JM. Evidence-based quality improvement: the state of the science. Health Aff (Millwood) 2005;24:138–50.

[26] Berwick DM. Continuous improvement as an ideal in health care. N Engl J Med 1989;320:53–6.

[27] Nelson EC, Godfrey MM, Batalden PB, Berry SA, Bothe AE, McKinley KE, et al. Clinical microsystems, Part1: The building blocks of health systems. Jt Comm J Qual Patient Saf 2008;34:367–

78.

[28] Schechter MS, Margolis P. Improving subspecialty healthcare: lessons from cystic fibrosis. J Pediatr 2005;147:295–301.

[29] Quinton HB, O'Connor GT, for the Northern New England CV Cystic Fibrosis Consortium. Current issues in quality improvement in cystic fibrosis. Clin Chest Med 2007;28:459–72.

[30] Stern M, Wiedemann B, Wenzlaff P, on behalf of the German Cystic Fibrosis Quality Assessment group. From registry to quality management: the German Cystic Fibrosis Quality Assessment project 1995– 2006. Eur Respir J 2008;31:29–35.

[31] Stern M. The use of a cystic fibrosis patient registry to assess outcomes and improve cystic fibrosis care in Germany. Curr Opin Pulm Med 2011;17:477–573.

[32] Ellemunter H, Eder J, Steinkamp G. Structured care in an ISO certified Centre for patients with cystic fibrosis and their families. Pneumologie 2011;65:615–23.

[33] Liou TG, Elkin EP, Pasta DJ, Jacobs JR, Konstan MW, Morgan WJ, et al. Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros 2010;9:250–6.

[34] Taylor-Robinson D, Whitehead M, Diderichsen F, Vebert Olesen H, Pressler T, Smyth RL, et al. Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study. Thorax 2012;67:860–6.

[35] Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, et al. Infection, inflammation and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011;184:75–81.

[36] Kraynack NC, McBride JT. Improving care at cystic fibrosis centers through quality improvement. Semin Respir Crit Care Med 2009;30:547–58.

[37] Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, et al. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros 2010;9:1–16.

[38] Glauser TA, Nevins PH, Williamson JC, Abdolrasulnia M, Salinas GD, Zhang J, et al. Adherence to the 2007 cystic fibrosis pulmonary guidelines: a national survey of CF care centers. Pediatr Pulmonol

2012;47:434–40.

[39] McPhail GL, Weiland J, Acton JD, Ednick M, Chima A, VanDyke R, et al. Improving evidence-based care in cystic fibrosis through quality improvement. Arch Pediatr Adolesc Med 2010;164:957–60.

[40] Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-based practice recommendations for nutrition-related manage- ment of children and adults with cystic fibrosis and

pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008;108:832–9.

[41] Moen IE, Nilsson K, Andersson A, Fagerland MW, Fluge G, Hollsing A, et al. Dietary intake and nutritional status in a Scandinavian adult cystic fibrosis population compared with recommendations. Food Nutr Res 2011;55:7561.

[42] Leonard A, Davis E, Rosenstein BJ, Zeitlin PL, Paranjape SM, Peeler D, et al. Description of a standardized nutrition classification plan and its relation to nutritional outcomes in children with cystic fibrosis. J Pediatr Psychol 2010;35:6–13.

[43] Stark LJ, Opipari-Arrigan L, Quittner AL, Bean J, Powers SW. The effects of an intensive behavior and nutrition intervention compared to standard of care on weight outcomes in CF. Pediatr Pulmonol

2011;46:31–5.

[44] Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006;173:475–82.

[45] CF Europe. http://www.cf-europe.eu/.

[46] Cystic Fibrosis Foundation Patient Registry. 2011 Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2011 [http://www.cff. org/research/ClinicalResearch/PatientRegistryReport].

[47] Goss HG, Quittner AL. Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc 2007;4:378–86.

[48] Mayer-Hamblett N, Ramsey BW, Kronmal AK. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007;4:370–7.

[49] European Medicines Agency. Committee for medicinal products for Human Use (CHMP). Guidelines on the Clinical Development of Medicinal Products for the Treatment of Cystic Fibrosis; Oct. 22 2009 [London, http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2009/12/WC500017055.pdf].

[50] Kerem E, Conway S, Elborn S, Heijerman H, for the Consensus Committee. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005;4(7–26):20.

[51] Steinkamp G, Schwarz C, Stahl K, Busche MCF. Care through the patient's eyes — a nationwide survey on patients' experience and satisfaction with services using a CF-specific questionnaire. Pediatr

Pulmonol 2012;47(S35):404 (abstract 492).

[52] Quon BS, Goss CH. A story of success: continuous quality improvement in cystic fibrosis care in the USA. Thorax 2011;66:1106–8.

[53] http://www.cftrust.org.uk/aboutus/annualreview/CF_Trust_Annual_Review_

2011_%28web%29.pdf.

[54] https://www.cysticfibrosis.org.uk/media/82070/CD_Standards_of_Care_Dec_11.pdf.

[55] http://www.cff.org/treatments/CFCareGuidelines/AgeSpecificCare/.

[56] Batalden PB, Davidoff F. What is “quality improvement” and how can it transform healthcare? Qual Saf Health Care 2007;16:2–3.

[57] Sermet-Gaudelus I, Mayell SJ, Southern KW. Guidelines on the early management of infants diagnosed with cystic fibrosis following newborn screening. J Cyst Fibros 2010;9:323–9.

[58] Mehta G, Macek Jr M, Mehta A, European RegistryWorking Group. Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. J Cyst Fibros 2010;9(Suppl. 2):5–21.

[59] World Health Organization. Guidance on developing quality and safety strategies with a health system approach. Copenhagen: World Health Organization Regional Office for Europe; 2008.

[60] Stern M, Niemann N, Wiedemann B, Wenzlaff P, German CFQA Group. Benchmarking improves quality in cystic fibrosis care: a pilot project involving 12 Centres. Int J Qual Health Care 2011;23:349–56.

[61] Ayers LR, Beyea SC, Godfrey MM, Harper DC, Nelson EC, Batalden PB. Quality improvement learning collaboratives. Qual Manag Health Care 2005;14:234–47.

[62] Rault G, Pougheon-Bertrand D, Gueganton L, Minguet G, Lombrail P. CF quality improvement program: a pilot phase to experiment the US QIP approach in France. Poster; ECFS Conference, Dublin, Ireland; June 6–9 2012. S60 M. Stern et al. / Journal of Cystic Fibrosis 13 (2014) S43–S59

[63] Schechter MS, Leonard A, Nash J, Quinton H, Richards K, Sabadosa K, et al. Benchmarking: signature themes. Pediatr Pulmonol 2006(Suppl. 29):122–3.

[64] Homchick RG, Hayward LR. Chapter 16. Peer review and quality assurance requirements. In: Tremaine DW, JD Organization, editors. 3rd ed. Washington Health Law Manual; 2009.

[65] World Health Organization. Quality of care: a process for making

strategic choices in health systems. Geneva: World Health Organization; 2006.

[66] Nelson EC, Batalden PB, Godfrey M. Measurement and monitoring. Quality by design: a clinical microsystems approach. Hoboken, NJ: John Wiley & Sons; 2007.

[67] McIntyre K, Shojania KG. The challenges of quality improvements reports and the urgent need for more of them. Thorax 2011;66:1020-2.

[68] Shaw CD, Kalo I. A background for national quality policies in health systems. Copenhagen: World Health Organization Regional Office for Europe; 2002.

[69] Kulich M, Rosenfeld M, Goss CH, Wilmott R. Improved survival among young patients with cystic fibrosis. J Pediatr 2003;142:631–6.

[70] Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of two year mortality. Am J Respir Crit Care Med

2002;166:1550–5.

[71] Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010;303:2386–92.

[72] Quon BS, Mayer-Hamblett N, Aitken ML, Smyth AR, Goss CH. Risk factors for chronic kidney disease in adults with cystic fibrosis. Am J Respir Crit Care Med 2011;184:1147–52.

[73] Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson A. Case–control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008;63:532–5.

[74] Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010;33:311–6.

[75] Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003;123:20–7.

[76] Döring G, Flume P, Heijerman H, Elborn JS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012;11:461–79.

[77] Schechter MS, Gutierrez HH. Improving the quality of care for patients with cystic fibrosis. Curr Opin Pediatr 2010;22:296–301.

[78] Kraynack NC, Gothard MD, Falletta LM, McBride JT. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011;46:870–81.

[79] Mott LS, Park J, Murray CP, Gangell CL, de Klerk NH, Robinson PJ, et al. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012;67:509–16.

[80] Sanders DB, Lai HJ, Rock MJ, Farrell PM. Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies. J Cyst Fibros 2012;11:150–3.

[81] Calvin J, Hogg SL, McShane D, McAuley SA, Iles R, Ross-Russell R, et al. Thirty-years of screening for cystic fibrosis in East Anglia. Arch Dis Child 2012;97:1043–7.

[82] Vernooij-van Langen AM, Loeber JG, Elvers B, Triepels RH, Gille JJ, Van der Ploeg CP, et al. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax 2012;67:289–95.

[83] Walshe K. International comparisons of the quality of health care: what do they tell us? Qual Saf Health Care 2003;12:4–5.

[84] Dreachslin JL, Zernott M, Mendenhall S, Nieuwenjuijsen ER. Data comparability issues in international research and quality assurance. Qual Assur Health Care 1993;5:143–56.

[85] Kerr EA, Asch SM, Hamilton EG, McGlynn EA, editors. Quality of care for general medical conditions: a review of the literature and quality indicators. Santa Monica, CA: RAND Corporation; 2000.

[86] Marshall MN, Shekelle PG, McGlynn EA, Campbell S, Brook RH, Roland MO. Can health care quality indicators be transferred between countries? Qual Saf Health Care 2003;12:8–12.

[87] Ellis J. Sharing the evidence: clinical practice benchmarking to improve continuously the quality of care. J Adv Nurs 2000;32:215-25.

[88] Goddard M, Mannion R, Smith P. Enhancing performance in health care: a theoretical perspective on agency and the role of information. Health Econ 2000;9:95–107.

[89] Sims G. International benchmarking from Centre level cystic fibrosis data. Pediatr Pulmonol 2010;45(S33):527.

[90] Conway S, Balfour-Lynn IM, De Rijcke K, Drevinek P, Foweraker J, Havermans T, et al. European Cystic Fibrosis Society Standards of Care: framework for the cystic fibrosis centre. J Cyst Fibros

2014;13:3–22.

[91] Gawande A. The bell curve. N Y Ann Med 2004 The New Yorker.

[92] Delaisi B, Grosskopf C, Reignault E, Goehrs JM, Navarro J. International registry on mucoviscidosis: comparison of the French data with the European data for 1995. Arch Pediatr 1998;5:384–8.

[93] Lai HC, Corey M, FitzSimmons S, Kosorok MR, Farrell PM. Comparison of growth status of patients with cystic fibrosis between the United States and Canada. Am J Clin Nutr 1999;69:531–8.

[94] Fogarty A, Hubbard R, Britton J. International comparison of median age at death from cystic fibrosis. Chest 2000;117:1656–60.

[95] Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M, et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001;31:1–12.

[96] McCormick J, Mehta G, Olesen HV, Viviani L, Macek Jr M, Mehta A, et al. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet 2010;375:1007–13.

[97] Knudsen PK, Olesen HV, Høiby N, Johannesson M, Karpati F, Laerum BN, et al. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis Centres in Denmark, Norway and Sweden. J Cyst Fibros 2009;8:135–42.

[98] Jackson AD, Daly L, Kelleher C, Marshall BC, Quinton HB, Foley L, et al. The application of current life table methods to compare cystic fibrosis median survival internationally is limited. J Cyst Fibros 2011;10:62–5.

[99] Boelle PY, Viviani L, Busson PF, Olesen H, Ravilly S, Stern M, et al. Reference percentiles for FEV1 and BMI in European children and adults with cystic fibrosis. Orphanet J Rare Dis 2012;7:64.

[100] Viviani L, Zolin A, Olesen HV. ECFSPR Annual Report 2008–2009. European Cystic Fibrosis Society Patient Registry; 2012.

[101] McCormick J, Sims EJ, Green MW, Mehta G, Culross F, Mehta A. Comparative analysis of Cystic Fibrosis Registry data from the UK with USA, France and Australasia. J Cyst Fibros 2005;4:115–22.

[102] Sims G. International benchmarking for cystic fibrosis patient outcomes using registry data. J Cyst Fibros 2009;8(S2):S103.

[103] Cystic fibrosis data network. http://www.cysticfibrosisdata.org/metadata- and-methodology.htm.

[104] Sims G. Outline and proposal for an international Cystic Fibrosis Data Network. http://www.cfww.org/programs/article/1319/Outline_and_proposal_for_an_international_Cystic_Fibrosis_Data_Network_April _ 2010; April 2010

Джерело: Clinical Guidelines: Care of Children with Cystic Fibrosis. Royal Brompton Hospital. S. Alexander et al. Endorsed by the Medicines Management Board of Royal Brompton & Harefield NHS Foundation Trust. 2014, The 6th edition

1. Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK. Second edition. December 2011. Consensus document outlining standards of care.

2. Pharmacy Standards of Care. November 2011. Consensus document outlining pharmacy standards in CF care.

3. Standards of Care and Good Clinical Practice for the Physiotherapy Management of Cystic Fibrosis. Second edition. June 2011. Consensus document outlining standards of care and food practice for physiotherapy.

4. Laboratory Standards for Processing Microbiological Samples from People with Cystic Fibrosis. First edition. September 2010.

5. Consensus document outlining laboratory standards for processing microbiological samples.

6. Antibiotic Treatment for Cystic Fibrosis. Third edition. May 2009. Consensus document on antibiotic treatment for CF.

7. Methicillin-resistant Staphylococcus aureus (MRSA). April 2008. Consensus document on MRSA

8. Bone Mineralisation in Cystic Fibrosis. February 2007. (Not to be downloaded without addendum, below). (PDF 762KB) Consensus document on bone mineralisation in CF.

9. Addendum for Bone Mineralisation in Cystic Fibrosis. Addendum for Bone Mineralisation consensus document.

10. Pseudomonas aeruginosa infection in people with Cystic Fibrosis. Suggestions for Prevention and Infection Control. Second Edition. November 2004.

11. Consensus document on prevention and infection control of Pseudomonas aeruginosa. The Burkholderia cepacia Complex - Suggestions for Prevention and Infection Control. Second edition. September 2004.

12. Consensus document on suggestions for prevention and infection control of Burkholderia cepacia Complex. Management of Cystic Fibrosis-related Diabetes Mellitus. June 2004.

13. Consensus document on managing CF-related diabetes mellitus. Nutritional Management of Cystic Fibrosis. April 2002.

14. Consensus document on nutritional management of CF. Clinical guidelines for the care of children with cystic fibrosis 2014 www.rbht.nhs.uk/childrencf 264 National Consensus Standards for the Nursing Management of Cystic Fibrosis. May 2001.

15. Consensus document on standards for nursing management of CF. Factsheets (Diagnosis) The sweat test in cystic fibrosis

16. A guide to the sweat test, what it is and how it is done. (Diagnosis) Finding out (a guide for parents of a child newly diagnosed with CF)

17. A factsheet for parents of a child newly diagnosed with cystic fibrosis. (Living with CF) Financial help

18. A factsheet about the financial help available for people with CF and their families, from the Cystic Fibrosis Trust and other organisations. (Living with CF) Higher education

19. A pack designed for adults with cystic fibrosis intending to go on to higher education. (Living with CF) Melioidosis and travel to tropical countries

20. A factsheet about melioidosis, an infection caused by Burkholderia pseudomallei. (Living with CF) Nutrition: A guide for adults

21. A factsheet about eating well with cystic fibrosis. (Living with CF) Nutrition: A guide for children and parents

22. A factsheet about eating well with cystic fibrosis. (Living with CF) Nutrition: A guide for feeding infants

23. A guide for feeding infants who have cystic fibrosis. (Living with CF) Housing

24. A pack of four factsheets on housing issues: choosing accommodation, renting, buying, and homelessness. (Living with CF) School and cystic fibrosis

25. A factsheet providing information on all aspects of cystic fibrosis and school, for teachers and parents. (CF care) A Patient's Charter: The care of patients with cystic fibrosis Factsheet outlining the essential health care people with CF should expect to receive.

26. (CF care) Support available from the Cystic Fibrosis Trust

27. An introduction to the support offered by the Cystic Fibrosis Trust. (CF care) Transition from paediatric to adult care: Guide for young people A guide for young people moving from paediatric to adult care.

28. (CF care) Transition from paediatric to adult care: Guide for parents A guide for parents with a child transferring to adult care.

СПИСОКЛіТЕРАТУРи, використанИЙ В ПРОЦЕСІ АДАПТАЦІЇ клінічної настанови

1. Ulrich Baumanna et al. Cost of care and clinical condition in paediatric cystic fibrosis patients Journal of Cystic Fibrosis 2 (2003) 84–90

2. Harry Heijerman et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus Journal of Cystic Fibrosis 8 (2009) 295–315

3. Haack A. et al. Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases World J Gastroenterol 2013 December 14; 19(46): 8552-8561

4. Kerem E. et al. Standards of care for patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis 4(2005) p.7-26

5. Castellani C., et al Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice Journal of Cystic Fibrosis 7 (2008) 179–196

6. S.C.Bell, P.J.Robinson, D.A.Fitzgerald. Cystic Fibrosis Standards of Care, Australia, 2008, North Ryde, Sydney, NSW, 2113.

7. S.J. Mayell et al. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis Journal of Cystic Fibrosis 8 (2009) 71–78 J Cyst Fibros. 2005 Mar;4(1):7-26.

8. Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK 9548511-1-0 December 2011 Second Edition

9. Lisa Saiman et al. CF Foundation Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update Recommendations for healthcare professionals Infection Control and Hospital Epidemiology, 03/07/2014. The University of Chicago Press. http://www.jstor.org/stable/10.1086/676882.

10. Peter J. Mogayzel Cystic Fibrosis Pulmonary Guidelines Chronic Medications for Maintenance of Lung Health Am J Respir Crit Care Med Vol 187, Iss. 7, pp 680–689, Apr 1, 2013 DOI: 10.1164/rccm.201207-1160OE

11. Malena Cohen-Cymberknoh et al. Managing Cystic Fibrosis Strategies That Increase Life Expectancy and Improve Quality of Life Am J Respir Crit Care Med Vol 183. pp 1463–1471, 2011

12. Miller M.R., J. Hankinson Series ‘‘Ats/Ers Task Force: Standardisation Of Lung Function Testing’’ Edited by V. Brusasco, R. Crapo and G. Viegi Eur Respir J 2005; 26: Eur Respir J 2005; 26: 153–338

13. Горовенко Н.Г. Проблеми діагностики та лікування муковісцидозу у дорослих, Здоровье Украины, номер 22/1 за декабрь 2008 года.

14. Муковисцидоз (Современные достижения и актуальные проблемы) Методические рекомендации. Под редакцией Капранова Н.И. и Каширской Н.Ю., Москва, 2011.

15. Guidelines for the management of pregnancy in women with cystic fibrosis. European Cystic Fibrosis Society. 2008;

16. South Australian Perinatal Practice Guidelines cystic fibrosis in pregnancy. 2015.